Establishing Micronutrient Deficiencies Impact on Metabolic Drugs-gut Microbiome Interactions
Year: 2025
Type: dissertation
Abstract: Atherosclerotic cardiovascular disease is the leading cause of mortality worldwide, and statin therapy is recommended for its prevention and management. By inhibiting 3-hydroxy-3- methylglutaryl-CoA reductase in the liver, statins lower Low-Density Lipoprotein (LDL) cholesterol levels. However, their efficacy varies between individuals. Because statins are absorbed in the gut, bidirectional interactions with the microbiota may contribute to this variability: drugs can alter microbial composition, while the microbiota can modulate drug bioavailability. Yet, the microbial targets of statins remain unclear. Recent work showed that high simvastatin concentrations upregulate genes encoding iron– sulfur cluster (Fe-S) proteins in Gram-positive gut bacteria. We hypothesized that statins might be toxic to gut bacteria by disrupting iron-related pathways. To test this, bacteria were cultured under iron-deficient conditions with statins; only simvastatin demonstrated synergy. Iron-binding assays and xanthine oxidase tests indicated no direct interaction with iron. Cell viability assays showed that Coprococcus comes, a common gut bacterium, became more sensitive to a membrane-disrupting agent under high simvastatin, suggesting Fe–S protein upregulation may be a collateral response to membrane disruption. These findings are preliminary and require further validation.
Author: Santos, Mafalda Barata dos
Institution: Universidade Nova de Lisboa
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7198543430
